Search

Author/Creator Reich, Steven D.

1. A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. (26th October 2017)

Authors:
Spencer, Andrew; Harrison, Simon; Zonder, Jeffrey; Badros, Ashraf; Laubach, Jacob; Bergin, Krystal; Khot, Amit; Zimmerman, Todd; Chauhan, Dharminder; Levin, Nancy; MacLaren, Ann; Reich, Steven D.; Trikha, Mohit; Richardson, Paul
Journal:
British journal of haematology
Issue:
Volume 180:Number 1(2018)
Page Start:
41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01)1. (December 2014)

Authors:
Yin, Donghua; Barker, Kerry B.; Li, Ruifeng; Meng, Xu; Reich, Steven D.; Ricart, Alejandro D.; Rudin, Dan; Taylor, Carrie T.; Zacharchuk, Charles M.; Hansson, Arne G.
Journal:
British journal of clinical pharmacology
Issue:
Volume 78:Number 6(2014:Dec.)
Page Start:
1281
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. (9th May 2016)

Authors:
Levin, Nancy; Spencer, Andrew; Harrison, Simon J.; Chauhan, Dharminder; Burrows, Francis J.; Anderson, Kenneth C.; Reich, Steven D.; Richardson, Paul G.; Trikha, Mohit
Journal:
British journal of haematology
Issue:
Volume 174:Number 5(2016)
Page Start:
711
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗